Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 12 (2025)
International Multidisciplinary Journal for Research & Development

Articles

LOWER URINARY TRACT SYMPTOMS (LUTS) IN MEN: MODERN DIAGNOSTIC AND THERAPEUTIC APPROACHES

Published 2025-12-19

  • Vahobov Lutfullo

Vahobov Lutfullo
Andijan State Medical Institute, Uzbekistan

Abstract

Lower urinary tract symptoms (LUTS) are highly prevalent among aging men and significantly affect quality of life. These symptoms are commonly associated with benign prostatic hyperplasia (BPH), but they may also arise from bladder dysfunction, neurological disorders, or systemic diseases. Advances in diagnostic methods and therapeutic strategies have improved the accuracy of diagnosis and the effectiveness of treatment. This article reviews current approaches to the evaluation and management of LUTS in men, emphasizing individualized, evidence-based care.

Keywords

lower urinary tract symptoms, LUTS, benign prostatic hyperplasia, urology, diagnosis, treatment.

PDF

References

  1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function. Neurourology and Urodynamics. 2002;21(2):167–178.
  2. Gratzke C., Bachmann A., Descazeaud A., et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms. European Urology. 2015;67(6):1099–1109.
  3. McVary K.T., Roehrborn C.G., Avins A.L., et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology. 2011;185(5):1793–1803.
  4. Roehrborn C.G. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia: Elsevier; 2021.
  5. Barry M.J., Fowler F.J., O’Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. Journal of Urology. 1992;148(5):1549–1557.
  6. Chapple C.R., Roehrborn C.G., McConnell J.D., et al. The role of alpha-blockers in the treatment of LUTS. European Urology. 2008;53(5):960–970.
  7. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin and finasteride on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine. 2003;349(25):2387–2398.
  8. Drake M.J., Chapple C., Esen A.A., et al. Efficacy and safety of mirabegron in men with overactive bladder and LUTS. European Urology. 2017;72(2):317–328.
  9. Kaplan S.A., Roehrborn C.G., Gong J., et al. Tolterodine extended release with or without tamsulosin in men with LUTS. Journal of Urology. 2006;175(3):999–1004.
  10. Foster H.E., Barry M.J., Dahm P., et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia. Journal of Urology. 2018;200(3):612–619.
  11. Parsons J.K., Dahm P., Köhler T.S., et al. Benign prostatic hyperplasia and male LUTS: Epidemiology and risk factors. Urology Clinics of North America. 2016;43(3):289–297.
  12. Cornu J.N., Ahyai S., Bachmann A., et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for LUTS. European Urology. 2015;67(6):1066–1096.
  13. Oelke M., Bachmann A., Descazeaud A., et al. EAU guidelines on the treatment and follow-up of non-neurogenic male LUTS. European Urology. 2013;64(1):118–140.
  14. Gacci M., Sebastianelli A., Salvi M., et al. The role of inflammation in benign prostatic hyperplasia. Nature Reviews Urology. 2016;13(10):545–554.
  15. Kim E.H., Larson J.A., Andriole G.L. Management of benign prostatic hyperplasia. Annual Review of Medicine. 2016;67:137–151.

Downloads

Download data is not yet available.